Healx, a pioneer in AI-powered drug discovery for rare and neglected conditions, has partnered with SCI Ventures - the world’s first specialist venture fund focused on curing paralysis- to accelerate ...

XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the ...

AI has been a buzzword in the pharmaceutical industry for almost a decade, with countless headlines promising to ...

Drug discovery has traditionally been slow, expensive and prone to failure, but AI and machine learning are set to change all ...

A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition.

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

Given the variability between labs and the unique nature of R&D work, custom, niche AI tools are going to become much more ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

Scientists at Shaanxi Normal University have developed an AI-powered dual-channel model that predicts miRNA–drug interactions with up to 96% ...

AstraZeneca has entered a strategic research collaboration with China's CSPC Pharmaceutical Group, aiming to accelerate the ...

At stake is a business that is projected to grow exponentially in the next decade. The market for AI-assisted drug discovery could reach US$13 billion by 2032 from US$1.5 billion in 2023, Coherent ...